COVID-19 treatments: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

COVID-19 treatments under rolling review

EMA’s CHMP is evaluating the following COVID-19 treatments:

TreatmentTreatment developerStart of rolling reviewMore information
REGN-COV2 (casirivimab / imdevimab) Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd (Roche)
Bamlanivimab and etesevimabEli Lilly11/03/2021
SotrovimabGlaxoSmithKline and Vir Biotechnology, Inc.07/05/2021EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19

COVID-19 treatments under marketing authorisation evaluation

EMA’s CHMP is evaluating the marketing authorisation application of the following COVID-19 treatment:

TreatmentTreatment developerStart of marketing authorisation evaluationMore information
Olumiant (baricitinib)Eli Lilly Nederland B.V.29/04/2021EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen
Kineret (anakinra)
Swedish Orphan Biovitrum AB (publ)


How useful was this page?

Add your rating
6 ratings
1 rating
2 ratings
5 ratings